187 related articles for article (PubMed ID: 18198283)
1. Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization.
Virk MS; Williams JT
Mol Pharmacol; 2008 Apr; 73(4):1301-8. PubMed ID: 18198283
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.
Virk MS; Arttamangkul S; Birdsong WT; Williams JT
J Neurosci; 2009 Jun; 29(22):7341-8. PubMed ID: 19494155
[TBL] [Abstract][Full Text] [Related]
3. Desensitization of functional µ-opioid receptors increases agonist off-rate.
Williams JT
Mol Pharmacol; 2014 Jul; 86(1):52-61. PubMed ID: 24748657
[TBL] [Abstract][Full Text] [Related]
4. Differential activation and trafficking of micro-opioid receptors in brain slices.
Arttamangkul S; Quillinan N; Low MJ; von Zastrow M; Pintar J; Williams JT
Mol Pharmacol; 2008 Oct; 74(4):972-9. PubMed ID: 18612077
[TBL] [Abstract][Full Text] [Related]
5. Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy.
Kovoor A; Celver JP; Wu A; Chavkin C
Mol Pharmacol; 1998 Oct; 54(4):704-11. PubMed ID: 9765514
[TBL] [Abstract][Full Text] [Related]
6. Two distinct forms of desensitization of G-protein coupled inwardly rectifying potassium currents evoked by alkaloid and peptide mu-opioid receptor agonists.
Blanchet C; Sollini M; Lüscher C
Mol Cell Neurosci; 2003 Oct; 24(2):517-23. PubMed ID: 14572471
[TBL] [Abstract][Full Text] [Related]
7. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
8. Morphine-Induced mu-opioid receptor desensitization.
Dang VC; Williams JT
Mol Pharmacol; 2005 Oct; 68(4):1127-32. PubMed ID: 16020743
[TBL] [Abstract][Full Text] [Related]
9. Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine.
Bailey CP; Couch D; Johnson E; Griffiths K; Kelly E; Henderson G
J Neurosci; 2003 Nov; 23(33):10515-20. PubMed ID: 14627635
[TBL] [Abstract][Full Text] [Related]
10. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S
Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397
[TBL] [Abstract][Full Text] [Related]
11. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
Baumhaker Y; Gafni M; Keren O; Sarne Y
Mol Pharmacol; 1993 Aug; 44(2):461-7. PubMed ID: 8394999
[TBL] [Abstract][Full Text] [Related]
12. Functional selectivity and time-dependence of μ-opioid receptor desensitization at nerve terminals in the mouse ventral tegmental area.
Lowe JD; Bailey CP
Br J Pharmacol; 2015 Jan; 172(2):469-81. PubMed ID: 24467517
[TBL] [Abstract][Full Text] [Related]
13. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
[TBL] [Abstract][Full Text] [Related]
14. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
15. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
16. Tolerance to the antinociceptive effect of morphine in the absence of short-term presynaptic desensitization in rat periaqueductal gray neurons.
Fyfe LW; Cleary DR; Macey TA; Morgan MM; Ingram SL
J Pharmacol Exp Ther; 2010 Dec; 335(3):674-80. PubMed ID: 20739455
[TBL] [Abstract][Full Text] [Related]
17. Mu opioid receptor-effector coupling and trafficking in dorsal root ganglia neurons.
Walwyn WM; Wei W; Xie CW; Chiu K; Kieffer BL; Evans CJ; Maidment NT
Neuroscience; 2006 Oct; 142(2):493-503. PubMed ID: 16887280
[TBL] [Abstract][Full Text] [Related]
18. Estimation of opioid receptor agonist dissociation constants with beta-chlornaltrexamine, an irreversible ligand which also displays agonism.
Leff P; Dougall IG
Br J Pharmacol; 1988 Sep; 95(1):234-40. PubMed ID: 2851350
[TBL] [Abstract][Full Text] [Related]
19. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of morphine analgesic effect with induction of mu-opioid receptor endocytosis in rats.
Hashimoto T; Saito Y; Yamada K; Hara N; Kirihara Y; Tsuchiya M
Anesthesiology; 2006 Sep; 105(3):574-80. PubMed ID: 16931992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
